This document provides a summary of key information from a Glaukos Corporation presentation:
- Glaukos is transforming glaucoma therapy through micro-scale injectable therapies like iStent that restore and enhance the eye's natural drainage system.
- Clinical trials show iStent used with cataract surgery significantly lowers intraocular pressure up to 3 years while reducing medication needs by over 80%.
- US retrospective studies of over 100 eyes found iStent with cataract surgery lowered pressure 22% and medications 56% at 2 years.
- An international study demonstrated iStent's pressure lowering ability increases with 1, 2, or 3 stents implanted as a standalone procedure.
This document provides an overview of Glaukos Corporation and its glaucoma treatment technologies:
- Glaukos has demonstrated strong revenue growth and profitability through the successful launch of its iStent device, which transforms glaucoma treatment from eye drops to a micro-invasive surgical procedure.
- The global glaucoma treatment market is large and growing due to an aging population, and current eye drop treatments have significant drawbacks.
- Glaukos is developing an advanced portfolio of micro-scale injectable therapies including the iStent Inject, iStent Supra, and iDose to treat glaucoma at different stages of progression and reduce dependency on eye drops.
- Clinical studies show
Glaukos investor presentation for web march 2017glaukos
This document provides an overview of Glaukos Corporation and its glaucoma treatment technologies. It summarizes Glaukos' 2016 accomplishments including strong sales growth and clinical trial progress. The document also summarizes clinical data showing the intraocular pressure and medication lowering capabilities of Glaukos' iStent technology. Finally, it outlines Glaukos' strategies to establish minimally invasive glaucoma surgery as the standard of care for treating open-angle glaucoma.
Glaukos investor presentation updated as of 11282016 for website posstingglaukos
Glaukos Corporation is a medical technology company transforming glaucoma treatment. Their solution portfolio includes minimally-invasive micro-scale injectable therapies to restore and enhance the eye's natural drainage system including the iStent, iStent Inject, and iStent Supra. Clinical trials demonstrate that a single iStent used in combination with cataract surgery achieves significant and sustained reductions in eye pressure and medication use through three years.
Glaukos Corporation is an ophthalmic medical technology company transforming glaucoma treatment. Their minimally-invasive micro-scale injectable therapies, including the iStent, provide more effective treatment options compared to eye drops and traditional surgeries. Clinical trials demonstrate the iStent used with cataract surgery significantly lowers intraocular pressure up to 3 years post-op while reducing medication use. Additional studies show promise for combination treatments and sustained efficacy of micro-scale injectable therapies.
Glaukos investor presentation q2 2016 for website 08032016glaukos
Glaukos Corporation is a medical technology company transforming glaucoma treatment. Their solution portfolio includes micro-scale injectable therapies to restore and enhance aqueous outflow including the iStent, iStent Inject, and iStent Supra. Clinical trials show the iStent reduces intraocular pressure and medication use when used with cataract surgery or as a standalone procedure. Glaukos has established global commercial operations and seized the first mover opportunity in key markets since US FDA approval of the iStent.
The document discusses Glaukos' solutions portfolio for treating glaucoma. It outlines their current micro-invasive glaucoma surgery device, the iStent, and clinical data showing sustained IOP reduction and medication reduction. It then introduces their vision to transform glaucoma treatment through micro-invasive surgical and pharmaceutical therapies, including a drug delivery implant to provide sustained drug therapy.
Glaukos investor presentation for q2 2017 for website and 8_kglaukos
This document discusses Glaukos Corporation and its glaucoma treatment technologies. It contains the following key points:
- Glaukos is transforming glaucoma therapy with micro-scale injectable treatments that restore eye's natural drainage and reduce intraocular pressure, the only proven treatment for glaucoma.
- Their flagship product, iStent, is a single-use micro-bypass stent that has demonstrated long-term IOP reduction and medication reduction when used with cataract surgery based on multiple clinical studies.
- New products in development include iStent Inject for combination cataract/glaucoma procedures, iStent Supra to access a secondary drainage pathway, and iDose for targeted
The document summarizes Glaukos Corporation's solutions portfolio for treating glaucoma. It outlines their current micro-invasive glaucoma surgery (MIGS) device, the iStent, and clinical data showing sustained IOP reduction and medication reduction. It then describes their vision to transform glaucoma treatment through MIGS technologies and sustained drug delivery therapies. This includes a drug-eluting implant to provide extended drug therapy and algorithms to optimize treatment based on disease severity.
This document provides an overview of Glaukos Corporation and its glaucoma treatment technologies:
- Glaukos has demonstrated strong revenue growth and profitability through the successful launch of its iStent device, which transforms glaucoma treatment from eye drops to a micro-invasive surgical procedure.
- The global glaucoma treatment market is large and growing due to an aging population, and current eye drop treatments have significant drawbacks.
- Glaukos is developing an advanced portfolio of micro-scale injectable therapies including the iStent Inject, iStent Supra, and iDose to treat glaucoma at different stages of progression and reduce dependency on eye drops.
- Clinical studies show
Glaukos investor presentation for web march 2017glaukos
This document provides an overview of Glaukos Corporation and its glaucoma treatment technologies. It summarizes Glaukos' 2016 accomplishments including strong sales growth and clinical trial progress. The document also summarizes clinical data showing the intraocular pressure and medication lowering capabilities of Glaukos' iStent technology. Finally, it outlines Glaukos' strategies to establish minimally invasive glaucoma surgery as the standard of care for treating open-angle glaucoma.
Glaukos investor presentation updated as of 11282016 for website posstingglaukos
Glaukos Corporation is a medical technology company transforming glaucoma treatment. Their solution portfolio includes minimally-invasive micro-scale injectable therapies to restore and enhance the eye's natural drainage system including the iStent, iStent Inject, and iStent Supra. Clinical trials demonstrate that a single iStent used in combination with cataract surgery achieves significant and sustained reductions in eye pressure and medication use through three years.
Glaukos Corporation is an ophthalmic medical technology company transforming glaucoma treatment. Their minimally-invasive micro-scale injectable therapies, including the iStent, provide more effective treatment options compared to eye drops and traditional surgeries. Clinical trials demonstrate the iStent used with cataract surgery significantly lowers intraocular pressure up to 3 years post-op while reducing medication use. Additional studies show promise for combination treatments and sustained efficacy of micro-scale injectable therapies.
Glaukos investor presentation q2 2016 for website 08032016glaukos
Glaukos Corporation is a medical technology company transforming glaucoma treatment. Their solution portfolio includes micro-scale injectable therapies to restore and enhance aqueous outflow including the iStent, iStent Inject, and iStent Supra. Clinical trials show the iStent reduces intraocular pressure and medication use when used with cataract surgery or as a standalone procedure. Glaukos has established global commercial operations and seized the first mover opportunity in key markets since US FDA approval of the iStent.
The document discusses Glaukos' solutions portfolio for treating glaucoma. It outlines their current micro-invasive glaucoma surgery device, the iStent, and clinical data showing sustained IOP reduction and medication reduction. It then introduces their vision to transform glaucoma treatment through micro-invasive surgical and pharmaceutical therapies, including a drug delivery implant to provide sustained drug therapy.
Glaukos investor presentation for q2 2017 for website and 8_kglaukos
This document discusses Glaukos Corporation and its glaucoma treatment technologies. It contains the following key points:
- Glaukos is transforming glaucoma therapy with micro-scale injectable treatments that restore eye's natural drainage and reduce intraocular pressure, the only proven treatment for glaucoma.
- Their flagship product, iStent, is a single-use micro-bypass stent that has demonstrated long-term IOP reduction and medication reduction when used with cataract surgery based on multiple clinical studies.
- New products in development include iStent Inject for combination cataract/glaucoma procedures, iStent Supra to access a secondary drainage pathway, and iDose for targeted
The document summarizes Glaukos Corporation's solutions portfolio for treating glaucoma. It outlines their current micro-invasive glaucoma surgery (MIGS) device, the iStent, and clinical data showing sustained IOP reduction and medication reduction. It then describes their vision to transform glaucoma treatment through MIGS technologies and sustained drug delivery therapies. This includes a drug-eluting implant to provide extended drug therapy and algorithms to optimize treatment based on disease severity.
The document discusses Glaukos Corporation's portfolio of micro-scale injectable glaucoma therapies and products in development. It summarizes key 2017 accomplishments including clinical trials, new product submissions, and international expansion. The document outlines Glaukos' vision to address the full range of glaucoma disease states with novel surgical and pharmaceutical therapies, highlighting the iDose travoprost intraocular drug delivery implant currently in Phase II clinical trials. Glaukos aims to deliver five new U.S. product introductions between 2018-2023 to transform glaucoma treatment.
The document discusses Glaukos Corporation, a medical technology company focused on glaucoma treatment. It provides an overview of Glaukos' micro-invasive glaucoma surgery technology and pipeline of micro-scale injectable therapies to treat the full spectrum of glaucoma disease. Key highlights include Glaukos' financial performance since its IPO, with over $300,000 iStents implanted globally and commercial sales in 15 countries. The document also provides details on iDose, an investigational travoprost drug delivery implant designed to continuously deliver medication directly into the eye over multiple years.
The document discusses Glaukos Corporation's efforts to develop micro-scale injectable therapies for treating glaucoma, including its iDose Travoprost implant. Preliminary results from a Phase II clinical trial of iDose Travoprost show average intraocular pressure reductions of 7.9-8.5 mmHg (32-33%) at 12 months, comparable to topical timolol. Patients using the implant also had lower average medication needs of 0.54 medications at 12 months. The implant aims to provide at least 6 months of intraocular pressure control with fewer side effects than eye drops to improve adherence to glaucoma treatment regimens.
Glaukos march 2018 ir presentation 03012018glaukos
The document discusses Glaukos Corporation, a medical technology company focused on glaucoma treatment. It provides an overview of Glaukos' product portfolio including the iStent, pipeline of micro-scale injectable therapies like iStent inject and iDose travoprost implant. It summarizes Glaukos' 2017 financial and operational performance including revenue growth, expansion into new markets, and progress advancing its product pipeline. The document positions Glaukos to address the full range of glaucoma disease states with its portfolio of MIGS and beyond therapies.
Impax provides an overview of its growth strategy, operations, generic and branded businesses, and 2014 financial outlook. The company's growth strategy focuses on internal and external R&D opportunities, M&A, and business development to drive revenue growth. Key generic products launched in 2013 include oxymorphone ER and authorized generics of Zomig and Trilipix. The branded pipeline includes RYTARY for Parkinson's disease and a bupivacaine patch for postherpetic neuralgia. For 2014, Impax forecasts adjusted gross margins in the low 50% range and expenses of $82-88M for generic R&D and $36-39M for branded R&D.
AMBS is a regenerative medicine company developing new treatments for CNS disorders and regenerative medicine. It has several programs and subsidiaries developing treatments for conditions like Parkinson's disease, burns, cancer, and retinal diseases. Its lead programs include Eltoprazine for Parkinson's disease levodopa-induced dyskinesia through its subsidiary Elto Pharma, and recombinant MANF protein for retinal conditions like retinitis pigmentosa through its subsidiary MANF Therapeutics. AMBS is currently trading at very low prices but has achieved much higher values in the past, and it believes further progress in its clinical programs could increase its valuation.
Our e-poster presented at the 9th Annual European Pharma Congress June 26-28, 2017 Madrid, Spain. Gain “ear-on-ground” knowledge on key drivers of big five pharma financial portfolios.
Independent assessment of investment worth based on unbiased analyst pool was presented in this e-poster in an easy reading format for rapid distillation of information
- The former head of the European Medicines Agency says that if the UK leaves the EU, the EMA will need to carefully manage issues arising from relocating, such as losing expert input from the UK medicines regulator MHRA.
- The consequences for the EU regulatory system and the EMA will depend on how Brexit negotiations unfold over the next two years as the UK divorces from the EU.
- If the EU insists on completing divorce proceedings before discussing the future UK-EU relationship, it could take years to negotiate new drug regulatory collaboration and the EMA may lose staff during the uncertain transition period.
Global Antibacterial Drugs Market 2017-2027Visiongain
For a report overview of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website:
https://www.visiongain.com/
https://www.visiongain.com/Report/1821/Global-Antibacterial-Drugs-Market-2017-2027
GlaxoSmithKline's ratios show deteriorating liquidity and increasing debt levels from 2009-2011. Current, quick, and cash ratios all declined, as did interest coverage. Debt ratios like debt-to-equity and debt-to-capital rose sharply. Profitability ratios declined in 2010 but recovered in 2011, with net profit margin, return on equity, and return on assets all improving. Inventory and receivables management was mixed, while payables turnover declined steadily.
Anterior Segment Company Showcase - Novaliq GmbHHealthegy
Novaliq has developed an artificial tear product called NovaTears/EvoTears that addresses the lipid layer of the tear film. It has been successfully launched in Europe. Novaliq is also developing treatments for dry eye, glaucoma, and retinal diseases using their proprietary EyeSol technology platform. Their pipeline includes products in development, clinical trials, and regulatory review.
The best stock broker and share broker in India, Rudra Shares & Stock Brokers Ltd. is member of all the leading Equity & commodity exchanges in India, dealing in stocks, shares, commodity & currency serving clientele in 18 states through 225 business partners. Rudra Shares Fundamental Call Report which will brief about Fundamental coverage of CADILA Healthcare Ltd
Amgen Cowen and Company 37th Annual Health Care Conference PresentationThe ScientifiK
This document summarizes an oral presentation given by David Meline, Executive Vice President and Chief Financial Officer of Amgen, at the Cowen and Company 37th Annual Health Care Conference on March 8, 2017. The presentation discusses Amgen's strong financial and operational execution in 2016, advancement of its innovative pipeline including positive cardiovascular outcomes data for Repatha, and growth opportunities across therapeutic areas like oncology, neuroscience, and bone health. It also reviews Amgen's biosimilars portfolio and strategy to invest in external innovation and deliver significant returns to shareholders through dividends and share repurchases.
The document discusses Novartis, a Swiss pharmaceutical company. It provides background on Novartis, including that it was created through a 1996 merger. It then discusses Novartis' case regarding an Indian patent, with timelines of key events from 1997 to 2009. Finally, it summarizes that Novartis spent very little (0.03%) of its Indian revenue on research and development in India, contradicting claims that restricting patents would reduce innovation.
Anterior Segment Company Showcase - Mati TherapeuticsHealthegy
Anterior Segment Company Showcase - Mati Therapeutics at OIS@AAO 2016.
Presenter:
Bob Butchofsky, Founder & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Interpace Diagnostics provides molecular diagnostic tests and pathology services to evaluate cancer risk. The presentation discusses:
1) Interpace's product portfolio including tests that risk-stratify pancreatic cysts, Barrett's esophagus, and thyroid nodules.
2) Clinical evidence and guidelines supporting their tests, and growth in adoption and coverage by payers.
3) Financial highlights including recent funding raises, revenue growth, and progress reducing costs.
4) Drivers for continued growth including expanding sales force and strategic partnerships.
This document provides an overview of G Medical Innovations and its mobile medical devices and monitoring services. It summarizes that G Medical develops FDA-approved mobile devices that collect diagnostic health data and enable remote patient monitoring to improve outcomes and reduce healthcare costs. The company has a growing portfolio of products and services and sees significant market potential to expand direct-to-consumer sales and the number of customers that include insurance providers, hospitals, clinics, and physicians. G Medical aims to capitalize on the large market for remote patient monitoring and digital health solutions to help manage the rising complexity and costs of healthcare.
Play to Win Q2 2021 Results
- Sanofi reported sales of €8.7 billion in Q2 2021, up 12% year-over-year, and business EPS of €1.38, up 16% year-over-year.
- Dupixent sales grew 57% year-over-year to €1.2 billion, driven by strong performance in both the US and ex-US markets.
- Vaccines sales increased by double digits to €1 billion in Q2 2021 compared to the same period in 2020.
- The presentation reviewed Sanofi's progress on priority R&D assets and initiatives to increase diversity and inclusion in the workplace.
Financial analysis of novartis pharmaceuticalsyashicaj9
Novartis Pharmaceuticals is an international healthcare company headquartered in Switzerland. The document analyzes Novartis' financial performance in India from 2012-2011 through ratio analysis. Key findings include:
1. Liquidity ratios like current and quick ratios show Novartis had a more satisfactory short-term financial position in 2011 compared to 2012.
2. Leverage and proprietary ratios measuring long-term solvency were satisfactory for both years.
3. Turnover ratios for inventory, fixed assets, and working capital were generally higher in 2011, indicating more efficient utilization of company resources that year compared to 2012.
4. Overall, the ratio analysis found Novartis' financial management
Exas may 2017 corporate presentation final1Exact Sciences
Exact Sciences is developing a pipeline of cancer diagnostic tests based on its methylation technology platform. It has validated methylation markers for the detection of lung, liver, and pancreatic cancers from blood samples, achieving sensitivity of 91-95% and specificity of 90-97%. The company's goal is to apply its platform to screen for and monitor additional cancers through liquid biopsy tests to enable earlier detection and guide treatment decisions. Exact Sciences reported first quarter 2017 revenues of $48.4 million, up from $35.2 million in the previous quarter, demonstrating accelerating adoption of its Cologuard colorectal cancer screening test.
Art 1236 rev c-valeritas investor deck 2.0_final_080618 web versionvaleritasir
Valeritas is a medical technology company focused on improving health and simplifying life for people with diabetes. Their flagship product, V-Go, is a wearable insulin delivery device for patients with type 2 diabetes. The presentation discusses Valeritas' significant market opportunity in the global diabetes pandemic, validates their new high-touch sales model which is driving accelerating revenue growth, and presents their attractive financial profile and path to profitability. Key risks to their projections include reliance on V-Go for revenue, ability to retain customers and achieve market acceptance, and manufacturing risks.
The document discusses Glaukos Corporation's portfolio of micro-scale injectable glaucoma therapies and products in development. It summarizes key 2017 accomplishments including clinical trials, new product submissions, and international expansion. The document outlines Glaukos' vision to address the full range of glaucoma disease states with novel surgical and pharmaceutical therapies, highlighting the iDose travoprost intraocular drug delivery implant currently in Phase II clinical trials. Glaukos aims to deliver five new U.S. product introductions between 2018-2023 to transform glaucoma treatment.
The document discusses Glaukos Corporation, a medical technology company focused on glaucoma treatment. It provides an overview of Glaukos' micro-invasive glaucoma surgery technology and pipeline of micro-scale injectable therapies to treat the full spectrum of glaucoma disease. Key highlights include Glaukos' financial performance since its IPO, with over $300,000 iStents implanted globally and commercial sales in 15 countries. The document also provides details on iDose, an investigational travoprost drug delivery implant designed to continuously deliver medication directly into the eye over multiple years.
The document discusses Glaukos Corporation's efforts to develop micro-scale injectable therapies for treating glaucoma, including its iDose Travoprost implant. Preliminary results from a Phase II clinical trial of iDose Travoprost show average intraocular pressure reductions of 7.9-8.5 mmHg (32-33%) at 12 months, comparable to topical timolol. Patients using the implant also had lower average medication needs of 0.54 medications at 12 months. The implant aims to provide at least 6 months of intraocular pressure control with fewer side effects than eye drops to improve adherence to glaucoma treatment regimens.
Glaukos march 2018 ir presentation 03012018glaukos
The document discusses Glaukos Corporation, a medical technology company focused on glaucoma treatment. It provides an overview of Glaukos' product portfolio including the iStent, pipeline of micro-scale injectable therapies like iStent inject and iDose travoprost implant. It summarizes Glaukos' 2017 financial and operational performance including revenue growth, expansion into new markets, and progress advancing its product pipeline. The document positions Glaukos to address the full range of glaucoma disease states with its portfolio of MIGS and beyond therapies.
Impax provides an overview of its growth strategy, operations, generic and branded businesses, and 2014 financial outlook. The company's growth strategy focuses on internal and external R&D opportunities, M&A, and business development to drive revenue growth. Key generic products launched in 2013 include oxymorphone ER and authorized generics of Zomig and Trilipix. The branded pipeline includes RYTARY for Parkinson's disease and a bupivacaine patch for postherpetic neuralgia. For 2014, Impax forecasts adjusted gross margins in the low 50% range and expenses of $82-88M for generic R&D and $36-39M for branded R&D.
AMBS is a regenerative medicine company developing new treatments for CNS disorders and regenerative medicine. It has several programs and subsidiaries developing treatments for conditions like Parkinson's disease, burns, cancer, and retinal diseases. Its lead programs include Eltoprazine for Parkinson's disease levodopa-induced dyskinesia through its subsidiary Elto Pharma, and recombinant MANF protein for retinal conditions like retinitis pigmentosa through its subsidiary MANF Therapeutics. AMBS is currently trading at very low prices but has achieved much higher values in the past, and it believes further progress in its clinical programs could increase its valuation.
Our e-poster presented at the 9th Annual European Pharma Congress June 26-28, 2017 Madrid, Spain. Gain “ear-on-ground” knowledge on key drivers of big five pharma financial portfolios.
Independent assessment of investment worth based on unbiased analyst pool was presented in this e-poster in an easy reading format for rapid distillation of information
- The former head of the European Medicines Agency says that if the UK leaves the EU, the EMA will need to carefully manage issues arising from relocating, such as losing expert input from the UK medicines regulator MHRA.
- The consequences for the EU regulatory system and the EMA will depend on how Brexit negotiations unfold over the next two years as the UK divorces from the EU.
- If the EU insists on completing divorce proceedings before discussing the future UK-EU relationship, it could take years to negotiate new drug regulatory collaboration and the EMA may lose staff during the uncertain transition period.
Global Antibacterial Drugs Market 2017-2027Visiongain
For a report overview of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website:
https://www.visiongain.com/
https://www.visiongain.com/Report/1821/Global-Antibacterial-Drugs-Market-2017-2027
GlaxoSmithKline's ratios show deteriorating liquidity and increasing debt levels from 2009-2011. Current, quick, and cash ratios all declined, as did interest coverage. Debt ratios like debt-to-equity and debt-to-capital rose sharply. Profitability ratios declined in 2010 but recovered in 2011, with net profit margin, return on equity, and return on assets all improving. Inventory and receivables management was mixed, while payables turnover declined steadily.
Anterior Segment Company Showcase - Novaliq GmbHHealthegy
Novaliq has developed an artificial tear product called NovaTears/EvoTears that addresses the lipid layer of the tear film. It has been successfully launched in Europe. Novaliq is also developing treatments for dry eye, glaucoma, and retinal diseases using their proprietary EyeSol technology platform. Their pipeline includes products in development, clinical trials, and regulatory review.
The best stock broker and share broker in India, Rudra Shares & Stock Brokers Ltd. is member of all the leading Equity & commodity exchanges in India, dealing in stocks, shares, commodity & currency serving clientele in 18 states through 225 business partners. Rudra Shares Fundamental Call Report which will brief about Fundamental coverage of CADILA Healthcare Ltd
Amgen Cowen and Company 37th Annual Health Care Conference PresentationThe ScientifiK
This document summarizes an oral presentation given by David Meline, Executive Vice President and Chief Financial Officer of Amgen, at the Cowen and Company 37th Annual Health Care Conference on March 8, 2017. The presentation discusses Amgen's strong financial and operational execution in 2016, advancement of its innovative pipeline including positive cardiovascular outcomes data for Repatha, and growth opportunities across therapeutic areas like oncology, neuroscience, and bone health. It also reviews Amgen's biosimilars portfolio and strategy to invest in external innovation and deliver significant returns to shareholders through dividends and share repurchases.
The document discusses Novartis, a Swiss pharmaceutical company. It provides background on Novartis, including that it was created through a 1996 merger. It then discusses Novartis' case regarding an Indian patent, with timelines of key events from 1997 to 2009. Finally, it summarizes that Novartis spent very little (0.03%) of its Indian revenue on research and development in India, contradicting claims that restricting patents would reduce innovation.
Anterior Segment Company Showcase - Mati TherapeuticsHealthegy
Anterior Segment Company Showcase - Mati Therapeutics at OIS@AAO 2016.
Presenter:
Bob Butchofsky, Founder & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Interpace Diagnostics provides molecular diagnostic tests and pathology services to evaluate cancer risk. The presentation discusses:
1) Interpace's product portfolio including tests that risk-stratify pancreatic cysts, Barrett's esophagus, and thyroid nodules.
2) Clinical evidence and guidelines supporting their tests, and growth in adoption and coverage by payers.
3) Financial highlights including recent funding raises, revenue growth, and progress reducing costs.
4) Drivers for continued growth including expanding sales force and strategic partnerships.
This document provides an overview of G Medical Innovations and its mobile medical devices and monitoring services. It summarizes that G Medical develops FDA-approved mobile devices that collect diagnostic health data and enable remote patient monitoring to improve outcomes and reduce healthcare costs. The company has a growing portfolio of products and services and sees significant market potential to expand direct-to-consumer sales and the number of customers that include insurance providers, hospitals, clinics, and physicians. G Medical aims to capitalize on the large market for remote patient monitoring and digital health solutions to help manage the rising complexity and costs of healthcare.
Play to Win Q2 2021 Results
- Sanofi reported sales of €8.7 billion in Q2 2021, up 12% year-over-year, and business EPS of €1.38, up 16% year-over-year.
- Dupixent sales grew 57% year-over-year to €1.2 billion, driven by strong performance in both the US and ex-US markets.
- Vaccines sales increased by double digits to €1 billion in Q2 2021 compared to the same period in 2020.
- The presentation reviewed Sanofi's progress on priority R&D assets and initiatives to increase diversity and inclusion in the workplace.
Financial analysis of novartis pharmaceuticalsyashicaj9
Novartis Pharmaceuticals is an international healthcare company headquartered in Switzerland. The document analyzes Novartis' financial performance in India from 2012-2011 through ratio analysis. Key findings include:
1. Liquidity ratios like current and quick ratios show Novartis had a more satisfactory short-term financial position in 2011 compared to 2012.
2. Leverage and proprietary ratios measuring long-term solvency were satisfactory for both years.
3. Turnover ratios for inventory, fixed assets, and working capital were generally higher in 2011, indicating more efficient utilization of company resources that year compared to 2012.
4. Overall, the ratio analysis found Novartis' financial management
Exas may 2017 corporate presentation final1Exact Sciences
Exact Sciences is developing a pipeline of cancer diagnostic tests based on its methylation technology platform. It has validated methylation markers for the detection of lung, liver, and pancreatic cancers from blood samples, achieving sensitivity of 91-95% and specificity of 90-97%. The company's goal is to apply its platform to screen for and monitor additional cancers through liquid biopsy tests to enable earlier detection and guide treatment decisions. Exact Sciences reported first quarter 2017 revenues of $48.4 million, up from $35.2 million in the previous quarter, demonstrating accelerating adoption of its Cologuard colorectal cancer screening test.
Art 1236 rev c-valeritas investor deck 2.0_final_080618 web versionvaleritasir
Valeritas is a medical technology company focused on improving health and simplifying life for people with diabetes. Their flagship product, V-Go, is a wearable insulin delivery device for patients with type 2 diabetes. The presentation discusses Valeritas' significant market opportunity in the global diabetes pandemic, validates their new high-touch sales model which is driving accelerating revenue growth, and presents their attractive financial profile and path to profitability. Key risks to their projections include reliance on V-Go for revenue, ability to retain customers and achieve market acceptance, and manufacturing risks.
Sanofi reported strong Q2 2022 results, with Dupixent sales nearly reaching €2 billion. Dupixent continues its outstanding performance with 43.4% sales growth year-over-year, driven by new indications and approvals in both the US and EU. Sanofi's pipeline is advancing with regulatory submissions for efanesoctocog alfa and nirsevimab expected in 2022. Positive data was also reported for the company's Beta-containing COVID-19 vaccine against variants including Omicron.
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Art 923 rev-c-updating investor presentation on valeritas website_final_12.05.16valeritasir
V-Go is a single-use, fully disposable insulin delivery device that provides basal and bolus insulin. It addresses the needs of the 4.6 million Type 2 diabetes patients in the US who require insulin but are not achieving treatment goals. Extensive clinical data shows V-Go lowers A1C levels and total daily insulin dose. It has established reimbursement through pharmacy benefits, making it cost-neutral for payors and patients compared to insulin pens. Valeritas sees significant growth opportunities by expanding its sales force to reach more prescribers.
Exact Sciences is becoming the leader in advanced cancer diagnostics by extending its Cologuard platform to next-generation liquid biopsy cancer diagnostics. Cologuard addresses the challenge of colorectal cancer screening by providing a non-invasive, easy-to-use test with high early-stage cancer sensitivity. Cologuard's commercial success is driven by expanding insurance coverage, growing physician adoption, and direct-to-consumer marketing campaigns.
Impax third quarter 2017 earnings call presentation impax-labs
Impax reported third quarter 2017 results and provided a business update. Key points include:
- Revenues declined year-over-year due to lower generic pricing, but increased sequentially driven by cost savings initiatives. Adjusted EBITDA and EPS also increased quarter-over-quarter.
- Generic division revenues declined year-over-year due to lower pricing, partially offset by higher volumes. Pricing declines moderated sequentially. The specialty pharmaceutical division saw revenue growth driven by higher product sales.
- Phase 2b results for Parkinson's treatment IPX203 showed significant reduction in "off time" compared to an immediate-release competitor, supporting advancement to Phase 3.
- Impax remains on track or ahead of
A Financial Review: Pharmaceuticals IndustryRoby Camagong
This Financial Review discusses the in-depth analysis of the operating and financial performance of the three companies in the Pharmaceutical Industry, namely- GlaxoSmithKline, Merck & Co, and Novartis. It compares the results of the companies from the past 5 FYE in relation to the financial ratios, industry economic indicators, company trends, business strengths and weaknesses, and management strategies.
3.31.17 exas april 2017 corporate presentationExact Sciences
This corporate presentation discusses Exact Sciences' mission to help eradicate colon cancer by partnering with various stakeholders. It summarizes the company's Cologuard test, which non-invasively screens for colorectal cancer with high sensitivity. Cologuard saw strong growth in 2016 and the presentation outlines Exact Sciences' commercial strategy and pipeline expansion into liquid biopsy tests for additional cancer types in collaboration with Mayo Clinic.
3.31.17 exas april 2017 corporate presentation v2Exact Sciences
Exact Sciences is working to establish Cologuard as the new standard for colon cancer screening by:
1) Increasing adoption through a national TV campaign and primary care sales force focused on educating physicians.
2) Growing revenue and test volume rapidly, with 152% revenue growth and over 68,000 tests completed in Q4 2016.
3) Expanding coverage with 77% of the addressable population now covered, including Medicare, following inclusion in screening guidelines.
This document discusses Ruthigen, Inc., a drug development company focused on developing RUT58-60, a hypochlorous acid-based drug candidate for invasive use. RUT58-60 aims to improve patient outcomes for invasive procedures by reducing post-surgical infections in a more effective way than current standard of care antibiotics. Published studies on Microcyn, another hypochlorous acid-based product, show promise in reducing infection rates for diabetic foot ulcers and coronary artery bypass graft surgery wounds. If successful, RUT58-60 could help hospitals reduce costs by shortening patient stays and lowering readmission rates for post-surgical infections.
Cowen & company health care conference march 7 2017 presentationimpax-labs
Impax provides a summary of its business operations and priorities for 2017. The company operates both specialty pharmaceutical and generic drug divisions. For its specialty division, Impax focuses on growing its Parkinson's drug Rytary and developing a next generation version. Its generic division has a diversified portfolio of 72 approved products and a pipeline of 43 potential products, including several opportunities for first-to-file or first-to-market generics. For 2017, Impax priorities include executing on specialty growth, maximizing generic profits, launching new generics, finding cost savings, and diversifying its portfolio.
Invitae's 36th Annual J.P. Morgan Healthcare Conference Presentationinvitaeir
This document discusses Invitae Corporation's growth and strategy in genetic testing. It notes that Invitae set new records in 2017 with over 134,000 samples accessioned and revenue of around $59 million. It aims to simplify genetic testing, make information more accessible, and transform the field from testing to information management. Invitae plans to continue growing in 2018, anticipating at least 250,000 samples and doubling its 2017 revenue to $120 million through expanding its product breadth, partnerships, and selective acquisitions.
This document provides an analysis of GlaxoSmithKline's (GSK) financial statements and business strategy. It first examines the pharmaceutical industry and GSK's competitive strategy of differentiation through heavy investment in research and development. It then reviews GSK's annual reports and accounting practices. Finally, it analyzes GSK's profitability ratios from 2009-2013, finding generally declining gross profit margins but increasing net profit margins over time.
Cowen and Company 37th Annual Health Care Conference Presentationimpax-labs
Impax provides a forward-looking statement regarding risks and uncertainties for its business. It discusses various risks including fluctuations in revenues and operating income, reliance on key customers and products, supply chain risks, competition, product development risks, and regulatory risks. Impax also outlines steps it has taken to reduce costs and optimize operations, with estimated annual savings of $40-50 million by 2018. Its priorities for 2017 include focusing on quality, executing specialty product growth, maximizing generics profits, and exploring more efficiencies.
Morgan stanley global healthcare conference 2014Quintiles2014
- Quintiles is a leading biopharmaceutical services company that provides drug development and integrated healthcare services.
- They have a track record of profitable growth with adjusted service revenues growing at an 8.3% CAGR from 2010-2013.
- Their vision is to "bring people and knowledge together for a healthier world" and their strategy focuses on differentiated offerings, new markets, and world-class customer relationships.
This presentation provides an overview of Interpace Diagnostics Group (IDXG), a commercial company that provides molecular diagnostic tests and pathology services for cancer evaluation. IDXG operates two CLIA-certified labs and has four proprietary molecular diagnostic tests for pancreatic cysts and thyroid nodules that assess cancer risk. The tests have high margins and barriers to entry due to reimbursement and complexity. Recent accomplishments include raising funds, improving financials, expanding insurance coverage and launching international distribution. The molecular diagnostic market is large and growing due to advantages over drug development. IDXG's tests establish new standards in cancer risk assessment for pancreatic cysts and thyroid nodules compared to current guidelines.
Global Trends in Medical Device and Diagnostic OEM Strategy and Implications ...Tony Freeman
Manning Advisors is pleased to announce the publication of its 2017 Global Trends in Medical Device and Diagnostic OEM Strategy and Implications for the Supply Chain. As in past years we looked at the major issues facing medical device OEMs and how those issues drive their relationship with their suppliers.
Our findings this year include:
Medical Device OEMs focusing on improved organic growth
2016 saw major OEMs relying heavily on acquisitions to improve revenues
OEMs see the eventual end of needle-moving acquisitions and are focusing on how to accelerate organic growth
Fee-for-value reimbursement and growing use of informatics are leading to redesign of product suites
The Supply Chain is consolidating around fewer, larger players
The supply chain is also consolidating via acquisitions
OEMs are embracing risk reduction by working with larger supply chain partners
The new threat to existing supply chain companies is the penetration of the market by giant global contract manufacturers like Flextronics and Celestica
Opportunity exists for smaller, nimble players who can assist OEMs in bring product to market more quickly
Opportunity also exists for specialized manufacturers
Feel free to contact me to discuss the issues or to arrange for an onsite presentation to your Board or management team. I look forward to an intriguing discussion.
You may reach me at tfreeman@manningadvisors.com or at (917) 868-0772 directly.
Best regards,
Tony Freeman, Managing Director
Manning Advisors LLC
90 Park Avenue, 17th Floor
New York, NY 10016
The document discusses trends in the specialty pharmacy industry and Diplomat Pharmacy's position to capitalize on these trends. It notes that specialty drugs are expected to grow from 25% to 50% of pharmacy industry revenues from 2011 to 2021. It also outlines how Diplomat has decades of experience in high-growth specialty categories, a growing portfolio of limited-distribution drugs, and is creating efficiencies to address increasing healthcare costs. The document positions Diplomat to benefit from industry trends through its multiple service lines and recent acquisitions.
Exas september 2017 corporate presentation finalExact Sciences
Exact Sciences presented their corporate strategy in September 2017. They discussed their mission to help eradicate colon cancer by partnering with various stakeholders. They highlighted that Cologuard addresses the challenges of colon cancer as a non-invasive screening test with high early-stage cancer detection rates. Exact Sciences also reviewed Cologuard's growing adoption driven by their commercial strategies like marketing, salesforce, and increasing insurance coverage.
Similar to Glaukos investor presentation for Q1 2017 (20)
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
MUTUAL FUNDS (ICICI Prudential Mutual Fund) BY JAMES RODRIGUESWilliamRodrigues148
Mutual funds are investment vehicles that pool money from multiple investors to purchase a diversified portfolio of stocks, bonds, or other securities. They are managed by professional portfolio managers or investment companies who make investment decisions on behalf of the fund's investors.
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4study presented by a Big 4